Phibro Animal Health's Cash & cash equivalent grew by 1.38 % in the Q1 2026 sequentially, while Current Liabilities decreased, this led to improvement in Phibro Animal Health's Quick Ratio to 0.28, Quick Ratio remained below Phibro Animal Health Corporation average.

Within Major Pharmaceutical Preparations industry 414 other companies have achieved higher Quick Ratio than Phibro Animal Health in first quarter 2026. While Quick Ratio total ranking in the first quarter 2026 has deteriorated compared to the prior quarter from 2411 to 3180.

Explain Quick Ratio?
How much Cash & cash equivalents PAHC�s has?
What are PAHC�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/PAHC/financial-strength

https://api.csimarket.com/api/v1/companies/PAHC/fundamentals

https://api.csimarket.com/api/v1/companies/PAHC/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

PAHC Quick Ratio	(Sep 30 2026) Q1	(Jun 30 2026) Q4	(Mar 31 2026) Q3	(Dec 31 2025) Q2	(Sep 30 2025) Q1
Y / Y Current Liabilities Change	98.46 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	-2.52 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	0.28	Subscribe	Subscribe	Subscribe	Subscribe
PAHC's Total Ranking	# 3180	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	-6.53 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	1.38 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio first quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 415
Healthcare Sector	# 802
Overall Market	# 3180

Quick Ratio Statistics
High	Average	Low
0.99	0.53	0.11
(Dec 31 2024)

Financial Statements
Phibro Animal Health's Current Liabilities	$ 296 Millions	Visit PAHC's Balance sheet
Phibro Animal Health's Cash & cash equivalent	$ 83 Millions	Visit PAHC's Balance sheet
Source of PAHC's Sales		Visit PAHC's Sales by Geography

Cumulative Phibro Animal Health's Quick Ratio

PAHC's Quick Ratio for the trailling 12 Months

PAHC Quick Ratio	(Sep 30 2026) 12 Months	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	52.95 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	5.59 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	0.3	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 2730	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	16.3 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	-0.67 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to PAHC Financial Strength Comparisons >> Go to Compare PAHC Quick Ratio to its Competitors

On the trailing twelve months basis Due to decrease in Current Liabilities in the Q1 2026 to $295.79 millions, cumulative Quick Ratio decreased to 0.3 above the PAHC average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 443 other companies have achieved higher Quick Ratio than Phibro Animal Health. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the fourth quarter 2026 from 3222 to 4090.

Explain Quick Ratio?
How much Cash & cash equivalents PAHC�s has?
What are PAHC�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 444
Healthcare Sector	# 909
Within the Market	#

trailing twelve months Quick Ratio Statistics
High	Average	Low
0.49	0.29	0.12
(Dec 31 2017)		(Dec 31 2014)

Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Sep 30 2026 MRQ Cash & cash equivalent	Sep 30 2026 MRQ Current Liabilities
Janux Therapeutics Inc	0.77	$ 41.818 Millions	$ 54.247 Millions
Arcus Biosciences Inc	0.76	$ 151.000 Millions	$ 199.000 Millions
Ligand Pharmaceuticals Incorporated	0.75	$ 374.303 Millions	$ 500.569 Millions
Alumis inc	0.73	$ 57.691 Millions	$ 79.405 Millions
Rockwell Medical inc	0.71	$ 10.750 Millions	$ 15.073 Millions
Ionis Pharmaceuticals Inc	0.68	$ 296.303 Millions	$ 435.292 Millions
Liquidia Corporation	0.68	$ 396.091 Millions	$ 585.397 Millions
Bristol myers Squibb Company	0.67	$ 12,581.000 Millions	$ 18,753.000 Millions
Harrow Inc	0.66	$ 75.336 Millions	$ 114.224 Millions
Supernus Pharmaceuticals inc	0.62	$ 176.171 Millions	$ 285.397 Millions
Axsome Therapeutics Inc	0.62	$ 313.859 Millions	$ 509.719 Millions
Inovio Pharmaceuticals Inc	0.59	$ 49.786 Millions	$ 84.038 Millions
Travere Therapeutics Inc	0.59	$ 123.542 Millions	$ 210.912 Millions
Clene Inc	0.58	$ 9.887 Millions	$ 17.114 Millions
Zoetis Inc	0.57	$ 1,533.000 Millions	$ 2,682.000 Millions
Organon and Co	0.55	$ 1,455.000 Millions	$ 2,652.000 Millions
Medicus Pharma Ltd	0.52	$ 5.020 Millions	$ 9.743 Millions
Gossamer Bio Inc	0.51	$ 51.189 Millions	$ 99.945 Millions
Bausch Health Companies Inc	0.51	$ 2,485.000 Millions	$ 4,895.000 Millions
Neonc Technologies Holdings Inc	0.49	$ 10.966 Millions	$ 22.241 Millions
Avenue Therapeutics Inc	0.47	$ 1.520 Millions	$ 3.210 Millions
Royalty Pharma Plc	0.46	$ 544.857 Millions	$ 1,179.003 Millions
Zymeworks Inc	0.45	$ 100.464 Millions	$ 223.931 Millions
Organogenesis Holdings Inc	0.45	$ 21.326 Millions	$ 47.649 Millions
Akari Therapeutics Plc	0.44	$ 5.743 Millions	$ 12.984 Millions
Inmed Pharmaceuticals Inc	0.43	$ 1.140 Millions	$ 2.673 Millions
Kiniksa Pharmaceuticals International Plc	0.43	$ 81.660 Millions	$ 191.855 Millions
Syndax Pharmaceuticals Inc	0.40	$ 146.094 Millions	$ 361.833 Millions
Vanda Pharmaceuticals Inc	0.40	$ 62.038 Millions	$ 154.980 Millions
Kura Oncology Inc	0.39	$ 57.937 Millions	$ 148.730 Millions

Date modified: 2026-11-06T12:55:29+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.